Healthcare
Live Price
Offline$0.0001
+0.00% today
1Y Change
+0.00%
Window
Jun 23, 2025 → Jun 15, 2026
Coverage: 248 bars · Jun 23, 2025 → Jun 15, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Rosetta Genomics Ltd. (ROSGQ) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and up 0.0% across the available one-year price window (Jun 23, 2025 → Jun 15, 2026). Baseline metrics include revenue growth of +11.7%, EPS growth of +32.5%, a dividend yield of 0.0%. What stands out right now is revenue +11.7%, EPS +32.5%, free cash flow +38.5% with operating margin -169.6% and ROIC -189.1%. Valuation is more restrained than many high-expectation growth names at price/sales 0.0. Stock Foundry combines ROSGQ price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
ROSGQ
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
ROSGQ Max Drawdown
-50.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for ROSGQ and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$201.0K
-50.4% YoY
FY Net Income
-$10.5M
+18.9% YoY
Free Cash Flow
-$8.9M
+20.7% YoY
Revenue Growth
+11.7%
EPS Growth
+32.5%
Gross Margin
19.4%
Net Margin
-175.8%
Income statement
USD
| Metric | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|
| Revenue | 9M | 8M | 1M | 405K | 201K |
| Gross Profit | 2M | 2M | 17K | -304K | -57K |
| Operating Income | -16M | -16M | -14M | -13M | -8M |
| EBITDA | -15M | -17M | -14M | -13M | -8M |
| Net Income | -16M | -17M | -15M | -13M | -10M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|
| Cash & Equivalents | 6M | 12M | 8M | 17M | 31M |
| Total Assets | 12M | 22M | 17M | 26M | 33M |
| Total Liabilities | 8M | 3M | 2M | 2M | 2M |
| Shareholder Equity | 4M | 20M | 15M | 24M | 31M |
| Total Debt | 4M | 0 | 0 | 0 | 0 |
| Net Debt | -2M | -12M | -8M | -17M | -31M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
9M
+18.6% YoY
Capital Expenditures
270K
+56.9% YoY
Free Cash Flow
9M
+20.7% YoY
Key ratios
Gross Margin
19.4%
Operating Margin
-169.6%
Net Margin
-175.8%
ROE
-135.1%
Debt / Equity
0.86x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.